Global PCR based transplant diagnostics market is expected to reach USD 995,007.52 thousand by 2031, from USD 612,500.00 thousand in 2023 growing at the CAGR of 6.5% in the forecast period of 2024 to 2031.
Market Segmentation
Global PCR based Transplant diagnostics Market, By Test Type (CMV PCR Test, EBV PCR Test, BKV PCR Test, VZV PCR Test, HSV1 PCR TestHSV2 PCR Test, Parvovirus B19 PCR Test, P. Jirovecii PCR Test, JCV PCR Test, Adenovirus PCR Test, and Aspergillus Spp PCR Test), By Transplant Type (Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Pancreas Transplantation, and Other Transplantations), Application (Diagnostic Applications and Research Applications), End User (Hospitals and Transplant Centers, Commercial Service Providers, Research Laboratories and Academic Institutes), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest Of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa )- Industry Trends and Forecast to 2031
Overview of Global PCR Based Transplant Diagnostics Market Dynamics
- Driver
- Increasing prevalence of organ failure
- Restraint
- Shortage of professionals with expertise in transplant diagnostics
- Opportunity
- Strategic initiation and technology launches by market players
Market Players
Some of the major market players for the global PCR based transplant diagnostics market are:
- Quest Diagnostics Incorporated.
- Laboratory Corporation of America Holdings.
- Eurofins Viracor, LLC
- Sonic Healthcare USA
- Dr Lal PathLabs
- ARUP Laboratories.
- Amber Lab
TABLE OF CONTENTS
1 INTRODUCTION 21
- 1.1 OBJECTIVES OF THE STUDY 21
- 1.2 MARKET DEFINITION 21
- 1.3 OVERVIEW OF THE GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET 21
- 1.4 CURRENCY AND PRICING 22
- 1.5 LIMITATIONS 22
- 1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
- 2.1 MARKETS COVERED 25
- 2.2 GEOGRAPHICAL SCOPE 26
- 2.3 YEARS CONSIDERED FOR THE STUDY 27
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
- 2.6 MULTIVARIATE MODELLING 32
- 2.7 TEST TYPE SEGMENT LIFELINE CURVE 32
- 2.8 MARKET END USER COVERAGE GRID 33
- 2.9 DBMR MARKET POSITION GRID 34
- 2.10 VENDOR SHARE ANALYSIS 35
- 2.11 SECONDARY SOURCES 36
- 2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 39
- 4.1 PESTAL ANALYSIS 42
- 4.2 PORTERS FIVE FORCES 43
5 MARKET OVERVIEW 44
- 5.1 DRIVERS 46
- 5.1.1 INCREASING PREVALENCE OF ORGAN FAILURE 46
- 5.1.2 RISING POPULARITY OF NON-INVASIVE DIAGNOSTIC METHODS 46
- 5.1.3 ADVANCEMENT IN ORGAN PRESERVATIVE TECHNIQUES 47
- 5.1.4 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES 48
- 5.2 RESTRAINTS 49
- 5.2.1 SHORTAGE OF PROFESSIONALS WITH EXPERTISE IN TRANSPLANT DIAGNOSTICS 49
- 5.2.2 HIGH COST OF PCR/NGS SOFTWARE 49
- 5.3 OPPORTUNITIES 50
- 5.3.1 STRATEGIC INITIATION AND TECHNOLOGY LAUNCHES BY MARKET PLAYERS 50
- 5.3.2 RISE IN GOVERNMENT SUPPORT AND FUNDING FOR PCR-BASED ORGAN TRANSPLANTATION 50
- 5.3.3 SURGE OF AWARENESS FOR ORGAN TRANSPLANTATION 51
- 5.4 CHALLENGES 52
- 5.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION 52
- 5.4.2 LACK OF ORGAN DONORS AND PROVIDERS ANNUALLY 53
6 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE 54
- 6.1 OVERVIEW 55
- 6.2 CMV PCR TEST 59
- 6.3 EBV PCR TEST 59
- 6.4 BKV PCR TEST 59
- 6.5 VZV PCR TEST 60
- 6.6 HSV1 PCR TEST 61
- 6.7 HSV2 PCR TEST 61
- 6.8 PARVOVIRUS B19 PCR TEST 61
- 6.9 P. JIROVECII PCR TEST 62
- 6.10 JCV PCR TEST 63
- 6.11 ADENOVIRUS PCR TEST 63
- 6.12 ASPERGILLUS SPP PCR TEST 64
7 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 65
- 7.1 OVERVIEW 66
- 7.2 KIDNEY TRANSPLANTATION 69
- 7.3 LIVER TRANSPLANTATION 70
- 7.4 HEART TRANSPLANTATION 70
- 7.5 LUNG TRANSPLANTATION 71
- 7.6 PANCREAS TRANSPLANTATION 71
- 7.7 OTHER TRANSPLANTATIONS 72
8 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 73
- 8.1 OVERVIEW 74
- 8.2 DIAGNOSTIC APPLICATIONS 77
- 8.3 RESEARCH APPLICATIONS 78
9 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER 79
- 9.1 OVERVIEW 80
- 9.2 HOSPITALS AND TRANSPLANT CENTERS 83
- 9.3 COMMERCIAL SERVICE PROVIDERS 84
- 9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 84
10 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION 85
- 10.1 OVERVIEW 86
- 10.2 NORTH AMERICA 89
- 10.2.1 U.S. 92
- 10.2.2 CANADA 94
- 10.2.3 MEXICO 96
- 10.3 EUROPE 98
- 10.3.1 FRANCE 101
- 10.3.2 U.K. 103
- 10.3.3 SPAIN 105
- 10.3.4 GERMANY 107
- 10.3.5 TURKEY 109
- 10.3.6 ITALY 111
- 10.3.7 RUSSIA 113
- 10.3.8 NETHERLANDS 115
- 10.3.9 BELGIUM 117
- 10.3.10 SWITZERLAND 119
- 10.3.11 REST OF EUROPE 121
- 10.4 ASIA-PACIFIC 122
- 10.4.1 CHINA 125
- 10.4.2 INDIA 127
- 10.4.3 SOUTH KOREA 129
- 10.4.4 AUSTRALIA 131
- 10.4.5 JAPAN 133
- 10.4.6 THAILAND 135
- 10.4.7 PHILIPPINES 137
- 10.4.8 INDONESIA 139
- 10.4.9 MALAYSIA 141
- 10.4.10 SINGAPORE 143
- 10.4.11 REST OF ASIA-PACIFIC 145
- 10.5 SOUTH AMERICA 146
- 10.5.1 BRAZIL 149
- 10.5.2 ARGENTINA 151
- 10.5.3 REST OF SOUTH AMERICA 153
- 10.6 MIDDLE EAST AND AFRICA 154
- 10.6.1 SAUDI ARABIA 157
- 10.6.2 ISRAEL 159
- 10.6.3 EGYPT 161
- 10.6.4 SOUTH AFRICA 163
- 10.6.5 U.A.E. 165
- 10.6.6 REST OF MIDDLE EAST AND AFRICA 167
11 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, COMPANY LANDSCAPE 168
- 11.1 COMPANY SHARE ANALYSIS: GLOBAL 168
- 11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 169
- 11.3 COMPANY SHARE ANALYSIS: EUROPE 170
- 11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 171
12 SWOT ANALYSIS 172
13 COMPANY PROFILES 173
- 13.1 QUEST DIAGNOSTICS INCORPORATED. 173
- 13.1.1 COMPANY SNAPSHOT 173
- 13.1.2 REVENUE ANALYSIS 173
- 13.1.3 COMPANY SHARE ANALYSIS 174
- 13.1.4 PRODUCT PORTFOLIO 174
- 13.1.5 RECENT DEVELOPMENTS 175
- 13.2 LABORATORY CORPORATION OF AMERICA HOLDINGS. 176
- 13.2.1 COMPANY SNAPSHOT 176
- 13.2.2 REVENUE ANALYSIS 176
- 13.2.3 COMPANY SHARE ANALYSIS 177
- 13.2.4 PRODUCT PORTFOLIO 177
- 13.2.5 RECENT DEVELOPMENT 178
- 13.3 EUROFINS VIRACOR 179
- 13.3.1 COMPANY SNAPSHOT 179
- 13.3.2 COMPANY SHARE ANALYSIS 179
- 13.3.3 PRODUCT PORTFOLIO 180
- 13.3.4 RECENT DEVELOPMENTS 181
- 13.4 SONIC HEALTHCARE LIMITED 182
- 13.4.1 COMPANY SNAPSHOT 182
- 13.4.2 PRODUCT REVENUE ANALYSIS 182
- 13.4.3 COMPANY SHARE ANALYSIS 183
- 13.4.4 PRODUCT PORTFOLIO 183
- 13.4.5 RECENT DEVELOPMENTS 184
- 13.5 DR LAL PATHLABS. 185
- 13.5.1 COMPANY SNAPSHOT 185
- 13.5.2 REVENUE ANALYSIS 185
- 13.5.3 COMPANY SHARE ANALYSIS 186
- 13.5.4 PRODUCT PORTFOLIO 186
- 13.5.5 RECENT DEVELOPMENTS 187
- 13.6 ARUP LABORATORIES 188
- 13.6.1 COMPANY SNAPSHOT 188
- 13.6.2 PRODUCT PORTFOLIO 188
- 13.6.3 RECENT DEVELOPMENT 188
- 13.7 AMBAR LAB. 189
- 13.7.1 COMPANY SNAPSHOT 189
- 13.7.2 PRODUCT PORTFOLIO 189
- 13.7.3 RECENT DEVELOPMENTS 189
14 QUESTIONNAIRE 190
15 RELATED REPORTS 193